SYDNEY, Jan 17, 2026, 16:55 AEDT — The market has closed.
- CSL (ASX:CSL) ended Friday at A$175.53, edging up 0.14%.
- CSL filed in the U.S. to register as many as 100 million American depositary shares.
- Attention turns to February results for updates on plasma therapies and vaccines.
CSL Limited (ASX:CSL) shares nudged up 0.14% to close at A$175.53 on Friday, wrapping up the Australian trading week. The move came after a U.S. securities filing linked to the company’s American depositary share program caught investors’ eyes.
The registration statement, filed on Form F-6, reveals Deutsche Bank Trust Company Americas has registered up to 100 million American depositary shares for CSL. These American depositary shares, or ADSs, are U.S.-listed receipts representing ordinary shares held by a depositary bank.
Mostly back-office plumbing, but it catches attention as investors gauge cross-border demand for a major healthcare player ahead of earnings season.
CSL’s shares fluctuated between A$174.35 and A$176.07 on Friday, with around 1.07 million shares exchanged, according to pricing data. The stock closed up A$0.25 from the previous day.
CSL climbed roughly 1% the previous day, buoyed by gains in Australian stocks driven by a strong materials sector and a solid healthcare segment. ResMed outperformed with a 2.4% jump during the same session.
Form F-6 is the registration document the U.S. SEC requires to list depositary shares represented by American depositary receipts. These receipts are issued by a depositary bank after taking custody of a foreign company’s securities, according to SEC instructions. Put simply, it lays out the legal groundwork for trading these receipts tied to shares already on record.
CSL is also traded over-the-counter in the U.S. under the ticker CSLLY, according to market data.
The main driver continues to be business performance, not regulatory hurdles. In October, CSL lowered its fiscal 2026 revenue growth forecast and trimmed profit growth estimates, blaming a steeper-than-anticipated decline in U.S. flu vaccination rates. The company also postponed the planned spin-off of its Seqirus vaccines division.
With the ASX closed for the weekend, traders are focusing on global risk sentiment and the Australian dollar heading into Monday. They’ll also be watching to see if defensive stocks continue attracting buyers. Moves in the U.S.-listed equivalents could offer an early glimpse of market mood.
CSL’s half-year results webcast is set for Feb. 11 at 10 a.m. AEDT. Investors will be focused on demand trends for plasma-derived therapies and what the company says about its vaccine outlook.
